Inhibición directa de la renina y protección de órganos diana. Más allá del descenso de la presión

Weber, 2006, Inhibiting the renin-angiotensin system to prevent cardiovascular disorders: Do we need a more comprehensive strategy, Rev Cardiovasc Med, 7, 45 Oh, 2007, Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension, J Am Coll Cardiol, 49, 1157, 10.1016/j.jacc.2006.11.032 Rashid, 2008, Direct renin inhibition: an evaluation of the safety and tolerability of Aliskiren, Curr Med Res Opin, 24, 2627, 10.1185/03007990802336541 Gradman, 2008, Current concepts: Renin inhibition in the treatment of hypertension, Curr Opin Pharmacol, 8, 120, 10.1016/j.coph.2008.01.003 Uresin, 2007, Efficacy and safety of the direct renin inhibitor Aliskiren and ramipril alone or in combination in patients with diabetes and hypertension, J Renin Angiotensin Aldosterone Syst, 8, 190, 10.3317/jraas.2007.028 Jordan, 2007, Direct renin inhibition with Aliskiren in obese patients with arterial hypertension, Hypertension, 49, 1047, 10.1161/HYPERTENSIONAHA.106.084301 Verdecchia, 2007, Safety and efficacy of the oral direct renin inhibitor Aliskiren in elderly patients with hypertension, Blood Press, 16, 381, 10.1080/08037050701717014 ASPIRE HIGHER clinical program expands to 35,000 patients in 14 trials, the largest cardio-renal outcomes program ever [citado 25 Jun 2010]. Disponible en: http://www.novartis.be/downloads/nl/pers-media/berichten/reports/2008-07-17_financialreport_s1-2008_en.pdf Mancini, 2004, Surrogate markers for cardiovascular disease: Structural markers, Circulation, 109, IV22, 10.1161/01.CIR.0000133443.77237.2f Solomon, 2009, Effect of the direct renin inhibitor Aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy, Circulation, 119, 530, 10.1161/CIRCULATIONAHA.108.826214 Westermann, 2008, Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure, Hypertension, 52, 1068, 10.1161/HYPERTENSIONAHA.108.116350 Solomon SD. Effect of the direct renin inhibitor Aliskiren on left ventricular remodelling following myocardial infarction with left ventricular dysfunction: ASPIRE. Presented at: American College of Cardiology 59th Annual Scientific Sessions; Atlanta, GA. Mar 13–16, 2010. Investigators, 2008, Telmisartan, ramipril or both in patients at high risk for vascular events, N Engl J Med, 358, 1547, 10.1056/NEJMoa0801317 Scirica, 2010, Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial, Eur Heart J, 31, 1993, 10.1093/eurheartj/ehq190 Seed, 2007, Neurohumoral effects of the new orally active renin inhibitor. Aliskiren, in chronic heart failure, Eur J Heart Fail, 9, 1120, 10.1016/j.ejheart.2007.09.002 McMurray, 2008, Effects of the oral direct renin inhibitor Aliskiren in patients with symptomatic heart failure, Circ Heart Fail, 1, 17, 10.1161/CIRCHEARTFAILURE.107.740704 McMurray JJV. Haemodynamic, neurohumoral, renal and ambulatory electrocardiographic effects of a new oral renin inhibitor in stable heart failure. Oral presentation at European Society of Cardiology Congress, Vienna, Austria. 1-5 September 2007. Latini, 2002, Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: The Valsartan Heart Failure Trial (Val-HeFT), Circulation, 106, 2454, 10.1161/01.CIR.0000036747.68104.AC Jafar, 2001, Angiotensin-converting enzymne inhibition and progression of renal disease. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease, Kidney Int, 60, 1131, 10.1046/j.1523-1755.2001.0600031131.x Klausen, 2004, Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes, Circulation, 110, 32, 10.1161/01.CIR.0000133312.96477.48 II Conferencia Internacional New Insights: progresión de la enfermedad renal crónica. Barcelona: Sociedad Española de Nefrología (SEN); 2005. Parving, 1974, Increased urinary albumin excretion rate in benign essential hypertension, Lancet, 1, 1190, 10.1016/S0140-6736(74)91002-2 Watchell, 2003, Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study, Ann Intern Med, 139, 901, 10.7326/0003-4819-139-11-200312020-00008 Gerstein, 2001, Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals, JAMA, 286, 421, 10.1001/jama.286.4.421 Casas, 2005, Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis, Lancet, 366, 2026, 10.1016/S0140-6736(05)67814-2 Ibsen, 2005, Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan Intervention For Endpoint reduction in hypertension study, Hypertension, 45, 198, 10.1161/01.HYP.0000154082.72286.2a Mancia, 2007, J Hypertens, 25, 1105, 10.1097/HJH.0b013e3281fc975a 2010 Canadian Hypertension Education Program (CHEP). Disponible en: http://hypertension.ca/chep Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161 Lewis, 2001, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med, 345, 851, 10.1056/NEJMoa011303 Parving, 2001, The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes, N Engl J Med, 345, 870, 10.1056/NEJMoa011489 Jacobsen, 2003, Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy, Kidney Int, 63, 1874, 10.1046/j.1523-1755.2003.00940.x Nakao, 2003, Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial, Lancet, 361, 117, 10.1016/S0140-6736(03)12229-5 Mann, 2008, Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial, Lancet, 372, 547, 10.1016/S0140-6736(08)61236-2 Persson, 2009, Renal effects of Aliskiren compared with and in combination with irbesartan in patients with Type 2 diabetes, hypertension and albuminuria, Diabetes Care, 32, 1873, 10.2337/dc09-0168 Parving, 2008, Aliskiren combined with losartan in Type 2 Diabetes and Nephropathy, N Engl J Med, 358, 2433, 10.1056/NEJMoa0708379 Buxton, 1997, Modelling in economic evaluation: an unavoidable fact of life, Health Econ, 6, 217, 10.1002/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.0.CO;2-W Cohen, 2008, Interpreting the results of cost-effectiveness studies, J Am Coll Cardiol, 52, 2119, 10.1016/j.jacc.2008.09.018 Brosa, 2009, Análisis costeefectividad de aliskiren en pacientes hipertensos, con diabetes tipo 2 y nefropatía ya tratados de forma óptima con ARA-II y otros fármacos antihipertensivos, PharmacoEconomics-Spanish Research Articles, 6, 95, 10.1007/BF03320855 López Bastida, 2002, Gac Sanit, 16, 334, 10.1016/S0213-9111(02)71933-X Delea, 2009, Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria, J Am Soc Nephrol, 20, 2205, 10.1681/ASN.2008111144 Cherney, 2010, The effect of direct renin inhibition on renal haemodynamic function, arterial stiffness and endothelial function in humans with uncomplicated Type 1 diabetes mellitus: A pilot study, Diabetes Care, 33, 361, 10.2337/dc09-1303 Nussberger, 2008, Renin inhibition by aliskiren prevents atherosclerosis progression: Comparison with irbesartan, atenolol, and amlodipine, Hypertension, 51, 1306, 10.1161/HYPERTENSIONAHA.108.110932 Imanishi, 2008, Renin inhibitor Aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes, Hypertension, 52, 563, 10.1161/HYPERTENSIONAHA.108.111120 Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients (AQUARIUS). ClinicalTrials.gov Identifier: NCT00853827. Parving, 2009, Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): Rationale and study design, Nephrol Dial Transplant, 24, 1663, 10.1093/ndt/gfn721 Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbimortality in Patients With Chronic Heart Failure (ATMOSPHERE). ClinicalTrials.gov Identifier: NCT00853658. Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure (ASTRONAUT). ClinicalTrials.gov Identifier: NCT00894387.